Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Lori J. Wirth(Massachusetts General Hospital), Roy B. Tishler(Dana-Farber Cancer Institute), Donald J. Annino(Harvard University), Paul M. Busse(Massachusetts General Hospital), Annie W. Chan(Harvard University), Charles M. Norris, Robert I. Haddad(Georgetown University), Aaron M. Allen(Tel Aviv University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Y. Li(First Affiliated Hospital Zhejiang University), J. Clark(Harvard University), Laura A. Goguen(Brigham and Women's Hospital)
Cited by 61
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926